Phroneme
Separate product candidate

Plain creatine monohydrate. No proprietary nootropic story.

Current evidence supports cautious interest in a possible modest memory benefit. It does not establish a general cognitive benefit, an IQ increase, disease prevention, longevity, or universal safety.

Release status
Not for sale

Checkout remains blocked pending independent regulatory, labeling, manufacturing, quality, and safety review.

Ingredient
Creatine monohydrate only
Blend
None
Market
United States only
Status
Product candidate, not for sale
Batch testing
Required before sale; no certificate published because no retail batch exists
Personalized dosing
Not offered

What the evidence permits us to say

Evidence and limitsmoderate

A 2024 meta-analysis found a possible modest memory benefit in adults; evidence for overall cognition and executive function was not significant.

Limit: The review included 16 trials and 492 participants; certainty was moderate for memory and low for several other cognitive outcomes.

The effects of creatine supplementation on cognitive function in adults

Safety screen before any future sale

Pregnancy, kidney disease, complex medication use, adverse symptoms, and concern about misuse trigger clinician or pharmacist guidance. Phroneme will not personalize dosing from lab data.

FDA claim boundary

Any future structure/function claim requires substantiation, FDA notification, and the required disclaimer. Disease claims remain prohibited.

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

FDA structure/function claims guidance ↗